Our Product Development department embraces teams focused on R&D, R&D Production, Medical Affairs and Regulatory Affairs and consist of more than 20 employees working both both our Belgian and Irish offices. We work on an exciting R&D pipeline of more than 65 niche generics and added-value generics and have more than 25 dossiers in our portfolio. More than 15 projects are already launched into more than 50+ markets World-wide. We are working with about 30 development centers and contract manufacturers World-wide.
We categorise our development projects into EU developments and US developments, where our portfolio today consists of 40 and 60%, respectively, but about 80% of new development projects are targeting the USA.
Our department is split into R&D injectable Team, R&D non-injectable team, R&D Production team, R&D Support team, Regulatory Affairs submission team and Medical Affairs team.
For more information about our company, please visit www.neogen.be.
Alter Pharma celebrates Official Opening and announces 80 new jobs in Balbriggan, Co Dublin
Friday, 23rd September, 2016 - Balbriggan, Co Dublin – Alter Pharma today officially inaugurated its new 48,000 sq. ft. Headquarters for its worldwide operations in Balbriggan, Co Dublin. The company also announced its plans to add 80 new jobs bringing total employment onsite to 120 by 2018. Alter Pharma CEO Pieter Van Rompay was joined by Minister for Jobs, Enterprise and Innovation Mary Mitchell O’Connor, and staff from its sister site in Belgium to officiate at the opening ceremony.
Minister for Jobs, Enterprise and Innovation, Mary Mitchell O'Connor T.D said "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of the fastest growing sectors. I welcome Alter Pharma's continued commitment to Ireland and its decision to base its HQ here is great news for both Balbriggan and Ireland. This is a continued testament to Ireland’s skilled workforce and I'm delighted that this investment will bring a further 80 jobs to Ireland.”
Welcoming the announcement Martin Shanahan, CEO IDA Ireland said “Alter Pharma develops and manufactures generic pharmaceutical drugs in a range of important disease areas such as oncology, cardiology and central nervous system disorders. Ireland continues to attract large scale investment in pharmaceuticals with generic pharmaceuticals contributing significantly to overall employment figures within the sector. This positive news from Alter Pharma serves to further build expertise and strengthen Ireland’s position within this competitive market.”
Please enter your email address
Please enter a valid email address